Polares Medical Secures $50 Million in Series C Funding for MRace Expansion in US Following Strong Clinical Results
Polares Medical SA has closed a $50 million Series C funding round, supported by DC Global Ventures, Lumination Capital, current investors, and a new strategic investor. The funding will accelerate clinical studies of the MR mitral valve replacement system, designed to enhance treatment options for mitral regurgitation. The system has been implanted in over 70 patients, yielding positive clinical outcomes, and will facilitate studies in the US, Europe, and Australia.
Theia Market Signal Identification - AI Assisted
Polares Medical has secured $50 million in a Series C funding round, backed by DC Global Ventures, Lumination Partners, existing investors, and a new strategic investor. This funding will advance the clinical studies of the MR mitral valve replacement system, which addresses the complexities of mitral regurgitation treatment.
The system has been implanted in over 70 patients, validating its concept and generating promising results. The raised funds will support further clinical studies in the US, Europe, and Australia.
Comments